. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: Hematol Oncol Clin North Am. 2014 Sep 26;28(6):1055–1071. doi: 10.1016/j.hoc.2014.08.005

Table 2.

Summary of results from the largest reported prospective studies of RIC HSCT in CLL

	Fred Hutchinson Cancer Center	German CLL Study Group	MD Anderson Cancer Center	Dana Farber Cancer Intitute

	Sorror et al. 2008⁵⁴	Dreger et al. 2010^53,62	Khouri et al. 2011⁵⁶	Brown et al. 2013⁵⁷
Number of patients	82	90	86	76
Conditioning regimen	Flu/low-dose TBI	Flu/Cy ± ATG	Flu/Cy ± R	Flu/Bu
Donors, % (sibling/MUR)	63/37	41/59	50/50	37/63
Median follow-up, months	60	72	37	61
Early mortality, % (<100d)	<10	<3	<3	<3
NRM, %	23	23	17	16
Acute grade 3-4 GvHD, %	20	14	7	17
Severe chronic GvHD, %	53	55	56	48
Median PFS, %	39 (5yrs)	38 (6yrs)	36 (6yrs)	43 (6yrs)
Median OS, %	50 (5yrs)	58 (6yrs)	51 (6yrs)	63 (6yrs)

Abbreviations: Flu – fludarabine; TBI – total body irradiation; Cy – cyclophosphamide; ATG - antithymocyte globulin; R – rituximab; Bu – busulfan; MUR – matched unrelated donor; NRM – non relapse mortality; GvHD – graft versus host disease; PFS – progression free survival; OS – overall survival.